Page 126 - 2019_05-HaematologicaMondo-web

D. Yehudai et al.
et al. Relationship between plasma concen-
trations of 3’-deoxy-3’-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis. 1994;170(6):1394-1403.
20. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38(12):2743-2749.
21. Birendra KC, DiNardo CD. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460-465.
22. Miller WH, Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene. 2002;21(21):3496- 3506.
23. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005; 106(8): 2841-2848.
24. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia. 2000;14:491-496.
25. Bröske A-M, Vockentanz L, Kharazi S, et al. DNA methylation protects hematopoietic stem cell multipotency from myeloery- throid restriction. Nat Genet. 2009;41(11): 1207-1215.
26. Gereige L-M, Mikkola HKA. DNA methy- lation is a guardian of stem cell self-renewal and multipotency. Nat Genet 2009;41(11): 1164-1166.
27. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell dif- ferentiation. Nat Genet. 2012;44(1):23-31.
28. Lechman ER, Gentner B, Ng SWK, et al.
miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016;29(4):602-606.
36. Lee Y-S, Kennedy WD, Yin YW. Structural Insight into Processive Human Mitochondrial DNA Synthesis and Disease- Related Polymerase Mutations. Cell. 2009;139(2):312-324.2018;32(3):165-174.
37. Wang TS. Eukaryotic DNA polymerases. Annu Rev Biochem. 1991;60(1):513-552.
38. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38(12):2743-2749.
39. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelo- cytic leukemia with tretinoin (all-trans- retinoic acid). N Engl J Med. 1991; 324(20):1385-1393.
40. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell. 2010;18(6):553-567.
41. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutantIDH2relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
42. Fiorese CJ, Schulz AM, Lin Y-F, Rosin N, Pellegrino MW, Haynes CM. The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR. Curr Biol. 2016;26(15):2037-2043.
43. Haynes CM, Yang Y, Blais SP, Neubert TA, Ron D. The matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in C. ele- gans. Mol Cell. 2010;37(4):529-540.
44. Nagaraj R, Sharpley MS, Chi F, et al. Nuclear Localization of Mitochondrial TCA Cycle Enzymes as a Critical Step in Mammalian Zygotic Genome Activation. Cell. 2017;168:210-223.e11.
29. Škrtić M, Sriskanthadevan S, Jhas B, et al. Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell. 2011; 20(5):674-688.
30. Ghosn J, Quinson A-M, Sabo N, et al. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial. HIV Med. 2007;8(3):142-147.
31. Otto MJ. New nucleoside reverse transcrip- tase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol. 2004; 4(5):431-436.
32. Kim E-Y, Vrang L, Öberg B, Merigan TC. Anti-HIV Type 1 Activity of 3′-Fluoro-3′- Deoxythymidine for Several Different Multidrug-Resistant Mutants. AIDS Res Hum Retroviruses. 2001;17(5):401-407.
33. Shen G, Ma H, Pang F, Ren P, Kuang A. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis. Acta Radiol. 2018;59(2):188-195.
34. Bahri H, Laurence L, Edeline J, et al. High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. J Nucl Med. 2014;55(11):1786- 1790.
35. Gerbaudo VH, Killoran JH, Kim CK, et al. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadju- vant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med. 2018;32(3):165-174.
972
haematologica | 2019; 104(5)